Back to Hematology
Hematologyv2016Evidence-Based

Central Nervous System International Prognostic Index (CNS-IPI)

Prognostic scoring system that predicts the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy. Helps identify patients who may benefit from CNS-directed prophylaxis and guides treatment planning decisions.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
cns ipi assessment
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Central Nervous System International Prognostic Index (CNS-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

CNS-IPI Score = Age >60 years (1) + LDH >normal (1) + ECOG PS >1 (1) + Ann Arbor stage III/IV (1) + >1 extranodal site (1) + Kidney/adrenal involvement (1). Total range: 0-6 points.

Clinical Pearls & Practice Notes

  • Developed for patients with DLBCL treated with R-CHOP chemotherapy
  • Validated in over 2,000 patients in original study
  • Low risk (0-1 points): 46% of patients, 0.6% CNS relapse rate at 2 years
  • Intermediate risk (2-3 points): 41% of patients, 3.4% CNS relapse rate at 2 years
  • High risk (4-6 points): 12% of patients, 10.2% CNS relapse rate at 2 years
  • Does not capture all high-risk patients - additional factors to consider
  • Additional high-risk features: breast, uterus, testis, epidural involvement
  • Bone marrow involvement and double-hit lymphomas also increase risk
  • MYC/BCL2 dual expression may modify risk assessment
  • Model helps avoid unnecessary CNS prophylaxis in low-risk patients
  • Approximately 90% of patients fall into low and intermediate risk categories
  • High-risk patients should be strongly considered for CNS prophylaxis
  • CNS prophylaxis options include intrathecal chemotherapy or high-dose methotrexate
  • Score should be calculated at initial diagnosis before treatment initiation
  • Validated across multiple international populations and healthcare systems
  • Used for treatment planning, patient counseling, and clinical trial stratification

Evidence & Literature Citations

  1. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016 Sep 10;34(26):3150-3156. doi: 10.1200/JCO.2015.65.6520.
  2. Ma'koseh M, Rahahleh N, Abdel-Razeq H. Impact of Central Nervous System International Prognostic Index on the Treatment of Diffuse Large B Cell Lymphoma. Cureus. 2021 Aug 13;13(8):e17016. doi: 10.7759/cureus.17016.
  3. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016 Apr 28;127(17):2182-8. doi: 10.1182/blood-2015-10-676700.

Score Interpretation Ranges

Low Risk0 – 1 pts

Very low CNS relapse risk

Intermediate Risk2 – 3 pts

Low to moderate CNS relapse risk

High Risk4 – 6 pts

High CNS relapse risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.